Fusion Biopsy
Jun 24, 2026
Fusion Biopsy: The Next Generation of Prostate Cancer Detection
Prostate cancer remains the second most common malignancy diagnosed in men worldwide, with global incidence now exceeding 1.4 million new prostate cancer cases a year. For decades, the diagnostic pathway leaned on a blunt instrument: a 12-core systematic biopsy taken largely by anatomical guesswork. That era is clo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
